hepatoАнналы хирургической гепатологииAnnaly khirurgicheskoy gepatologii = Annals of HPB Surgery1995-54642408-9524НЭИКОН ИСП10.16931/1995-5464.2025-1-86-93hepato-1212Research ArticleЖЕЛЧНЫЕ ПРОТОКИBILE DUCTSНейроэндокринные опухоли желчного пузыря: клинические характеристики, лечение и выживаемость на примере девяти наблюденийGallbladder neuroendocrine neoplasms: clinical characteristics, management, and survival in nine caseshttps://orcid.org/0000-0002-3264-2441TidjaneА.TidjaneA.

Anisse Tidjane – Professor, Department of Hepatobiliary Surgery, EHU-1st November 1954, University of Oran 1.

Oran

Anisse Tidjane – Professor, Department of Hepatobiliary Surgery, EHU-1st November 1954, University of Oran 1.

Oran

tidjane.anisse@univ-oran1.dzhttps://orcid.org/0000-0002-8282-4534BengueddachA.BengueddachA.

Aicha Bengueddach – Associatte Professor, Department of Medical Oncology, EHU-1st November 1954, University of Oran 1.

Oran

Aicha Bengueddach – Associatte Professor, Department of Medical Oncology, EHU-1st November 1954, University of Oran 1.

Oran

aicha.bengueddach@gmail.comhttps://orcid.org/0000-0001-6547-0714KadriA.KadriA.

Amine Kadri – Doctor, Head of Laboratory, Laboratoire d’Anatomie Pathologique, Dr Kadri.

Oran

Amine Kadri – Doctor, Head of Laboratory, Laboratoire d’Anatomie Pathologique, Dr Kadri.

Oran

kadridiagnostic@gmail.comhttps://orcid.org/0009-0006-5295-6049DerricheH.DerricheH.

Hamid Derriche – Doctor, Head of Department, Etablissement Hospitalier Kara.

Oran

Hamid Derriche – Doctor, Head of Department, Etablissement Hospitalier Kara.

Oran

h.derriche@cliniquekara.dzhttps://orcid.org/0000-0001-8695-6297IkhlefN.IkhlefN.

Nacim Ikhlef – Doctor, Department of Hepatobiliary Surgery, EHU-1st November 1954, University of Oran 1.

Oran

Nacim Ikhlef – Doctor, Department of Hepatobiliary Surgery, EHU-1st November 1954, University of Oran 1.

Oran

ikhlef2000@yahoo.frhttps://orcid.org/0000-0001-6144-9408IarbiH.LarbiH.

Hakim Larbi – Doctor, Department of Hepatobiliary Surgery, EHU-1st November 1954, University of Oran 1.

Oran

Hakim Larbi – Doctor, Department of Hepatobiliary Surgery, EHU-1st November 1954, University of Oran 1.

Oran

larbi.hkmed@yahoo.frhttps://orcid.org/0000-0003-2622-4507MansouriJu.MansouriJu.

Juba Mansouri – Doctor, Department of Hepatobiliary Surgery, EHU-1st November 1954, University of Oran 1.

Oran

Juba Mansouri – Doctor, Department of Hepatobiliary Surgery, EHU-1st November 1954, University of Oran 1.

Oran

jubamansouri91@gmail.comhttps://orcid.org/0000-0001-6198-6879MeharziS. I.MeharziS. I.

Sif Islem Meharzi – Doctor, Department of Hepatobiliary Surgery, EHU-1st November 1954, University of Oran 1.

Oran

Sif Islem Meharzi – Doctor, Department of Hepatobiliary Surgery, EHU-1st November 1954, University of Oran 1.

Oran

meharzisif@live.frhttps://orcid.org/0000-0001-7881-5523KehiliH.KehiliH.

Hakima Kehili – Professor, Department of Medical Oncology, EHU-1st November 1954, University of Oran 1.

Oran

Hakima Kehili – Professor, Department of Medical Oncology, EHU-1st November 1954, University of Oran 1.

Oran

kehili.hakima@univ-oran1.dzhttps://orcid.org/0009-0000-6389-5209OurabahA.OurabahA.

Anissa Ourabah – Doctor Department of Hepatobiliary Surgery, EHU-1st November 1954, University of Oran 1.

Oran

Anissa Ourabah – Doctor Department of Hepatobiliary Surgery, EHU-1st November 1954, University of Oran 1.

Oran

anissa.ourabah@hotmail.comhttps://orcid.org/0000-0002-3391-2335TabetiB.TabetiB.

Benali Tabeti – Professor, Head of Department, Department of Hepatobiliary Surgery, EHU-1st November 1954, University of Oran 1.

Oran

Benali Tabeti – Professor, Head of Department, Department of Hepatobiliary Surgery, EHU-1st November 1954, University of Oran 1.

Oran

btabeti@yahoo.frDepartment of Hepatobiliary Surgery, EHU-1st November 1954, University of Oran 1АлжирDepartment of Hepatobiliary Surgery, EHU-1st November 1954, University of Oran 1AlgeriaDepartment of Medical Oncology, EHU-1st November 1954, University of Oran 1АлжирDepartment of Medical Oncology, EHU-1st November 1954, University of Oran 1AlgeriaLaboratoire d’Anatomie Pathologique, Dr KadriАлжирLaboratoire d’Anatomie Pathologique, Dr KadriAlgeriaEtablissement Hospitalier KaraАлжирEtablissement Hospitalier KaraAlgeria2025280220253018693Copyright © Tidjane А., Bengueddach A., Kadri A., Derriche H., Ikhlef N., Iarbi H., Mansouri J., Meharzi S.I., Kehili H., Ourabah A., Tabeti B., 20252025Tidjane А., Bengueddach A., Kadri A., Derriche H., Ikhlef N., Iarbi H., Mansouri J., Meharzi S.I., Kehili H., Ourabah A., Tabeti B.Tidjane A., Bengueddach A., Kadri A., Derriche H., Ikhlef N., Larbi H., Mansouri J., Meharzi S.I., Kehili H., Ourabah A., Tabeti B.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://hepato.elpub.ru/jour/article/view/1212

Нейроэндокринные опухоли желудочно-кишечного тракта и панкреатобилиарной системы являются редкими злокачественными новообразованиями, при этом нейроэндокринные новообразования желчного пузыря составляют менее 0,5% всех нейроэндокринных опухолей.

Цель

Цель. Описание клинических особенностей, стратегий лечения и исходов нейроэндокринных новообразований желчного пузыря у пациентов, проходивших лечение в западной части Алжира.

Материал и методы

Материал и методы. Проведен ретроспективный анализ девяти наблюдений нейроэндокринных новообразований желчного пузыря, диагностированных с декабря 2015 по сентябрь 2024 г. из общего числа пациентов с нейроэндокринными опухолями желудочно-кишечного тракта и панкреатобилиарной системы (301 пациент). Собранные данные включали возраст, пол, клинические проявления, градацию опухоли, индекс Ki-67, стадии, методы лечения и выживаемость.

Результаты

Результаты. Из 9 пациентов (6 женщин и 3 мужчин, средний возраст 58,56 года) у 4 диагностированы хорошо дифференцированные нейроэндокринные опухоли, у 5 — крупноклеточные нейроэндокринные карциномы. Общие клинические проявления включали боль в правом подреберье (100%), желтуху (22%), пальпируемую опухоль (33%) и потерю массы тела (56%). Трем больным удалось выполнить хирургическое вмешательство R0, достигнуты негативные края резекции. Общая выживаемость составила 8,7 мес, при этом выживаемость пациентов, перенесших радикальную операцию, в среднем составила 17,7 месяцев по сравнению с 4,2 мес у пациентов без операции. У пациентов с желтухой отмечена меньшая выживаемость: средняя выживаемость пациентов с желтухой составила 2,5 мес, пациентов без желтухи — 10,4 мес.

Заключение

Заключение. Нейроэндокринные новообразования желчного пузыря являются редкими опухолями и представляют определенные клинические трудности. Настоящее исследование подчеркивает важность ранней диагностики и агрессивного лечения, при этом желтуха служит критическим прогностическим фактором. Хирургическое вмешательство обеспечивает потенциальные преимущества в выживаемости, хотя необходимы дальнейшие исследования для уточнения стратегий лечения этих редких новообразований.

Aims

Aims: Gastrointestinal and pancreatobiliary neuroendocrine tumors (GNETs) are rare malignancies, with gallbladder neuroendocrine neoplasms (GB-NENs) representing less than 0.5% of all NETs. This study aims to describe the clinical features, management strategies, and outcomes of gallbladder neuroendocrine neoplasms treated within the West Algerian NET Network.

Materials and Methods

Materials and Methods. A retrospective analysis was conducted on 9 cases of gallbladder neuroendocrine neoplasms diagnosed between December 2015 and September 2024 from a total of 301 patients with Gastrointestinal and pancreatobiliary neuroendocrine tumors. Data were collected on age, sex, clinical findings, tumor grade, Ki-67 levels, stage, management, and survival outcomes.

Results

Results. Among the 9 patients (6 females, 3 males; mean age: 58.56 years), 4 had well-differentiated NETs, and 5 had large cell neuroendocrine carcinomas. Common clinical presentations included right hypochondrial pain (100%), jaundice (22%), palpable mass (33%), and weight loss (56%). Surgical resection was performed in 3 cases, achieving R0 resection with negative margins. The overall survival was 8.7 months, with those undergoing curative surgery surviving a mean of 17.7 months compared to 4.2 months for non-surgical patients. Jaundice at diagnosis was significantly associated with poorer survival (mean survival: 2.5 months vs. 10.4 months without jaundice.

Conclusion

Conclusion. Gallbladder neuroendocrine neoplasms are rare tumors that present unique clinical challenges. This case series highlights the importance of early diagnosis and aggressive management, with jaundice at presentation serving as a critical prognostic factor. Surgical resection appears to offer potential survival benefits, though further studies are needed to refine management strategies for these rare neoplasms.

нейроэндокринные опухолиновообразование желчного пузыряпрогнозхирургияжелтухаneuroendocrine tumorsgallbladder neoplasmprognosissurgeryjaundiceReferencesAhmed M. Gastrointestinal neuroendocrine tumors in 2020. World J. Gastrointest. Oncol. 2020; 12 (8): 791. https://doi.org/10.4251/wjgo.v12.i8.791Ahmed M. Gastrointestinal neuroendocrine tumors in 2020. World J. Gastrointest. Oncol. 2020; 12 (8): 791. https://doi.org/10.4251/wjgo.v12.i8.791Rindi G., Mete O., Uccella S., Basturk O., La Rosa S., Brosens L.A.A., Ezzat S., de Herder W.W., Klimstra D.S., Papotti M., Asa S.L. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocr. Pathol. 2022; 33 (1): 115–154. https://doi.org/10.1007/s12022-022-09708-2Rindi G., Mete O., Uccella S., Basturk O., La Rosa S., Brosens L.A.A., Ezzat S., de Herder W.W., Klimstra D.S., Papotti M., Asa S.L. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocr. Pathol. 2022; 33 (1): 115–154. https://doi.org/10.1007/s12022-022-09708-2Tidjane A., Boudjenan N., Bengueddach A., Kadri A., Ikhlef N., Benmaarouf N., Tabeti B. Pure large cell neuroendocrine carcinoma of the gallbladder, is surgical relentlessness beneficial? A case report and literature review. Int. Cancer Conf. J. 2021; 10 (2): 127. https://doi.org/10.1007/s13691-020-00461-zTidjane A., Boudjenan N., Bengueddach A., Kadri A., Ikhlef N., Benmaarouf N., Tabeti B. Pure large cell neuroendocrine carcinoma of the gallbladder, is surgical relentlessness beneficial? A case report and literature review. Int. Cancer Conf. J. 2021; 10 (2): 127. https://doi.org/10.1007/s13691-020-00461-zCai X.C., Wu S.D. Gallbladder neuroendocrine carcinoma diagnosis, treatment and prognosis based on the SEER database: A literature review. World J. Clin. Cases. 2022; 10 (23): 8212–8223. https://doi.org/10.12998/wjcc.v10.i23.8212Cai X.C., Wu S.D. Gallbladder neuroendocrine carcinoma diagnosis, treatment and prognosis based on the SEER database: A literature review. World J. Clin. Cases. 2022; 10 (23): 8212–8223. https://doi.org/10.12998/wjcc.v10.i23.8212Miyamoto R., Kikuchi K., Uchida A., Ozawa M., Nagai K., Maeda M., Kemmochi A., Inagawa S., Yamamoto M. Large cell neuroendocrine carcinoma of the gallbladder: a case report and literature review. Int. Surg. 2016; 101 (9–10): 458–464. https://doi.org/10.9738/INTSURG-D-16-00122.1Miyamoto R., Kikuchi K., Uchida A., Ozawa M., Nagai K., Maeda M., Kemmochi A., Inagawa S., Yamamoto M. Large cell neuroendocrine carcinoma of the gallbladder: a case report and literature review. Int. Surg. 2016; 101 (9–10): 458–464. https://doi.org/10.9738/INTSURG-D-16-00122.1Dasari B.V.M., Ionescu M.I., Pawlik T.M., Hodson J., Sutcliffe R.P., Roberts K.J., Muiesan P., Isaac J., Marudanayagam R., Mirza D.F. Outcomes of surgical resection of gallbladder cancer in patients presenting with jaundice: A systematic review and meta-analysis. J. Surg. Oncol. 2018; 118 (3): 477–485. https://doi.org/10.1002/jso.25186Dasari B.V.M., Ionescu M.I., Pawlik T.M., Hodson J., Sutcliffe R.P., Roberts K.J., Muiesan P., Isaac J., Marudanayagam R., Mirza D.F. Outcomes of surgical resection of gallbladder cancer in patients presenting with jaundice: A systematic review and meta-analysis. J. Surg. Oncol. 2018; 118 (3): 477–485. https://doi.org/10.1002/jso.25186Yang X.W., Yuan J.M., Chen J.Y., Yang J., Gao Q.G., Yan X.Z., Zhang B.H., Feng S., Wu M.C. The prognostic importance of jaundice in surgical resection with curative intent for gallbladder cancer. BMC Cancer. 2014; 14 (1): 652. https://doi.org/10.1186/1471-2407-14-652Yang X.W., Yuan J.M., Chen J.Y., Yang J., Gao Q.G., Yan X.Z., Zhang B.H., Feng S., Wu M.C. The prognostic importance of jaundice in surgical resection with curative intent for gallbladder cancer. BMC Cancer. 2014; 14 (1): 652. https://doi.org/10.1186/1471-2407-14-652IHPBA-APHPBA International Study Group of Gallbladder Cancer; Palepu J., Endo I., Chaudhari V.A., Murthy G.V.S., Chaudhuri S. et al. ‘IHPBA-APHPBA clinical practice guidelines’: international Delphi consensus recommendations for gallbladder cancer. HPB (Oxford). 2024; 26 (11): 1311–1326. https://doi.org/10.1016/j.hpb.2024.07.411IHPBA-APHPBA International Study Group of Gallbladder Cancer; Palepu J., Endo I., Chaudhari V.A., Murthy G.V.S., Chaudhuri S. et al. ‘IHPBA-APHPBA clinical practice guidelines’: international Delphi consensus recommendations for gallbladder cancer. HPB (Oxford). 2024; 26 (11): 1311–1326. https://doi.org/10.1016/j.hpb.2024.07.411Tidjane A., Boudjenan-Serradj N., Khalifa S., Ikhlef N., Bengueddach A., Larbi H. et al. Adenosquamous carcinoma of gallbladder associated with biliopancreatic maljunction and Todani 1c choledochal cyst: A case report. Adv. Dig. Med. 2023; 10 (3): 184–188.Tidjane A., Boudjenan-Serradj N., Khalifa S., Ikhlef N., Bengueddach A., Larbi H. et al. Adenosquamous carcinoma of gallbladder associated with biliopancreatic maljunction and Todani 1c choledochal cyst: A case report. Adv. Dig. Med. 2023; 10 (3): 184–188.Gogna S., Samson D., Gachabayov M., Rojas A., Felsenreich D.M., Koo D., Gu K., Quintero L., Miller K.R., Azim A., Da Eric Dong X. Neuroendocrine neoplasms of the gallbladder: early detection and surgery is key to improved outcome. Langenbecks Arch. Surg. 2022; 407 (1): 197–206. https://doi.org/10.1007/s00423-021-02256-zGogna S., Samson D., Gachabayov M., Rojas A., Felsenreich D.M., Koo D., Gu K., Quintero L., Miller K.R., Azim A., Da Eric Dong X. Neuroendocrine neoplasms of the gallbladder: early detection and surgery is key to improved outcome. Langenbecks Arch. Surg. 2022; 407 (1): 197–206. https://doi.org/10.1007/s00423-021-02256-zArrivi G., Verrico M., Roberto M., Barchiesi G., Faggiano A., Marchetti P., Mazzuca F, Tomao S. Capecitabine and temozolomide (CAPTEM) in advanced neuroendocrine neoplasms (NENs): a systematic review and pooled analysis. Cancer Manag. Res. 2022; 14: 3507–3523. https://doi.org/10.2147/CMAR.S372776Arrivi G., Verrico M., Roberto M., Barchiesi G., Faggiano A., Marchetti P., Mazzuca F, Tomao S. Capecitabine and temozolomide (CAPTEM) in advanced neuroendocrine neoplasms (NENs): a systematic review and pooled analysis. Cancer Manag. Res. 2022; 14: 3507–3523. https://doi.org/10.2147/CMAR.S372776

The authors declare that there are no conflicts of interest present.